



Dr. Stephen Chia, MD, FRCP(C)


Stephen K. Chia, MD, FRCP (Canada), is an Associate Professor of Medicine in the Department of Medicine at the University of British Columbia, Vancouver, Canada. He also is a staff medical oncologist with the British Columbia Cancer Agency (BCCA), Vancouver Centre. Dr. Chia also serves as Chair for the British Columbia Breast Tumour Group, Chair of the BCCA Tumour Group Council, and is physician coordinator for both the breast cancer and head and neck cancer clinical trials at the BCCA – Vancouver Cancer Centre (VCC). He was also recently appointed a Subject Editor for the British Journal of Cancer.

Dr. Chia received his bachelor's degree in Pharmacology from the University of British Columbia, where he also earned his medical degree in 1993 and obtained his Internal Medicine Fellowship and Medical Oncology Fellowship. He then completed post-fellowship training from 1999 to 2000 with the Department of Advanced Therapeutics – British Cancer Research Centre and with the Institute of Molecular Medicine at the University of Oxford.

He is currently a member of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) Executive Committee, the NCIC CTG Breast Executive Committee, the NCIC IND Executive Committee, and the NCIC CTG Breast Correlative Science Committee. He is a past member of the American Society of Clinical Oncology (ASCO) Scientific Committee (2009 to 2012), ASCO Breast Symposium Committee (2014-2015) and served as a Breast Track chair (Triple Negative/Cytotoxic/Local) for the ASCO 2011 Annual Meeting. An active researcher in phase 1 to 3 trials in breast cancer and investigational new drugs, Dr. Chia has an established interest in neoadjuvant systemic therapy for breast cancer and drug development. He has spearheaded the efforts for the BCCA – VCC to be the first Canadian site for the I-SPY2 consortium. He is currently carrying out clinical and translational studies in breast cancer with peer-reviewed, grant-funded research from the NCIC, National Institutes of Health (USA), Canadian Breast Cancer Research Alliance, and Canadian Breast Cancer Foundation – British Columbia/Yukon Chapter.


Dr. Chia has been widely published (more than 85 peer-reviewed publications) in international peer-reviewed journals including The New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Journal of the National Cancer Institute, Cell, Annals of Oncology, and Clinical Cancer Research. Recently he has written the Commentaries in Lancet and Lancet Oncology for the latest EBCTCG Overview (2011), NOAH study (2010), GEPARQUINTO study (2012), and the BOLERO-3 study (2014) respectively.

Dr. Chia has been overall study PI on a large phase III clinical trial (EFFECT) as well as being on academic steering committees (ASC) for various other phase II and III trials (ExteNET, TRY-PHAENA, MONALEESA-3, RxPONDER). He also sits on the correlative science committee for the ALTO/NeoALTO clinical trial. He closely collaborates with researchers at the BC Cancer Research Centre (more so with Dr. Samuel Aparicio and Dr. Francois Benard) and helped initiate the primary xenograft program in patients undergoing neoadjuvant chemotherapy at the BCCA (Eirew P, et al. Nature 2014) and was involved in the study of the sequencing of primary triple negative breast cancers (Shah S, et al. Nature 2012). Dr. Chia has also led studies with the prognostic/predictive assays of PAM50 and Oncotype DX in primary breast cancers (Chia S, et al. Clin Cancer Res 2012; Chia S, et al. Eur J Cancer 2013).



Dr. Anthony Fyles, MD, FRCP(C)

Dr. Tony Fyles is a member of the Princess Margaret Cancer Program at the University Health Network. He did his MD degree and postgraduate training in Radiation Oncology at the University of Toronto and Royal Marsden Hospital. He has research interests in translational and drug development clinical trials in gynecologic cancer, clinical studies of the tumour microenvironment, and clinical trials in breast cancer. He is Professor in the Departments of Radiation Oncology and Obstetrics and Gynecology at the University of Toronto.



Dr. Karen Gelmon, MD

Dr. Gelmon is a Professor of Medicine at the UBC and a Medical Oncologist at the BCCA, combining clinical and translational research. She is currently Head of the Division of Medical Oncology at the UBC. She is Co Chair of the Breast Site Committee for the NCIC Trials Group and a member of the NCI Breast Steering Committee and was a member of the BIG (Breast International Group) Advisory Group. She sits on the NCIC-CTG executive and is a past Chair of this committee. She is also a Komen scholar and member of the Scientific Advisory Council for Komen and Co Chair of the Scientific Advisory Council of the Ontario Institute of Cancer Research. She is Clinical leader of Advanced Therapeutics department at the BCCA. She sits on the International Advisory Board of The Lancet, The Oncologist and Clinical Breast Cancer. She is a reviewer for journals and grant review panels. She has been track teacher interested in education of health care professionals and the public and has published extensively. She has been a member of the Board of the BC Cancer Foundation, on the Medical Advisory Board of the BC/Yukon Chapter of the Canadian Breast Cancer Foundation and sits on the board of Rethink Breast Cancer. She was the recipient of the YWCA Woman of Distinction award in 2003 and an humanitarian award in 2011. She is the mother of two daughters and is active on volunteer boards for the arts and community in Vancouver.



Dr. Iain Lyburn

Is Consultant Radiologist Gloucestershire Hospitals NHS FT, Medical Director and Lead for Molecular Imaging in Cheltenham Imaging Center, also He is Clinical Director of Gloucestershire Breast Screening Programme as well as a Visiting Professor at University of Cranfield and President of United Kingdom Radiological Congress (UKRC)

Dr. Lyburn has a several radiological commitments in a wide range of subspecialities, particularly within oncology imaging like CT, MRI, Nuclear Medicine (including PET/CT) & Breast imaging. His main research interests predominantly is clinically orientated focusing on PET, MR and Breast Imaging; collaboration with a teams from the University of Exeter and University of Cranfield on basic science projects.

He is an Associate Editor of many journals such as:

Clinical Radiology- appointed January 2010; Journal of Radiology Case Reports – appointed August 2013

Also, Dr. Lyburn is an Invited Manuscript Reviewer for journals with publishing bases in a wide range of locations – UK, Continental Europe, North America and Australasia: British Journal of Radiology, The Breast Journal, Journal of Gastroenterology & Hepatology, European Radiology, Annals of Nuclear Medicine, British Journal of Surgery, Nuclear Medicine Communications, Clinical Radiology, Injury.



Dr. Jean-Marc Nabholz

Professor Nabholz moved recently to the Division of Oncology-Hematology/ Department of Medicine of the King Saud University Medical City in Riyadh with the mission to build a National and International Cancer Research Program. French trained, He spent 16 years in North America as Professor of Medicine and Oncology at the University of California at Los Angeles (UCLA), USA, and Director of the Cancer Therapy Development Program as well as Director of the Solid Tumor Program at the Jonsson Comprehensive Cancer Center at UCLA. He held as well a Professorship at the University of Alberta, Edmonton, Canada. During the last 5 years, he was Chairman of the Department of Medicine and Director of the Division of Clinical and Translational Research at the Jean Perrin Regional Comprehensive Cancer Centre of Auvergne, Clermont-Ferrand, France. He is also the Founder and past Chairman of one of the largest global breast cancer clinical research group (Breast Cancer International Research Group / BCIRG). He is focusing on cancer patient care and the development of new biologic therapies in oncology as well as on the integration of global clinical and translational research and care processes. As Breast Cancer medical oncology specialist, his main interests and achievements are related to several topics:

(i) Chemotherapy, in particular taxanes: Beyond being the leading author of the first registration randomized trial of paclitaxel in advanced breast cancer (1993), he designed the global strategy of development of docetaxel in breast cancer, being chairman of several pivotal registration randomized trials with this agent. He has also developed strategies and participated in the development of Caelyx, 3rd generation taxanes, Etoposide B and Capecitabine.

(ii) Hormone therapy, particularly in the development of third generation aromatase inhibitors. He is the leading author of one of the 2 registration randomized trials of anastrozole in advanced breast cancer as well as member of the ATAC steering committee (registration trial of anastrozole in early breast cancer).

(iii) New biologic modifiers in breast cancer, leading pivotal phase III trials for Herceptin mainly in adjuvant breast cancer and in the development of new biology-oriented combinations with Herceptin and new biologic modifiers. He is also involved in the development of anti-EGFR monoclonal antibodies, as well as inhibitors of mTOR and PI3K.

(iv) Development of new translational as well as clinical research processes in oncology with global integration of means for streamlining the clinical development and integrating Genomics, Transcriptomics and Proteomics in screening, prediction of treatment efficacy and tumor evolution towards individualized medicine. Development of the innovative Cancer Quantum Optics program (collaboration between the Max Planck Institute in Garching, Germany and King Saud University in Riyadh, KSA) and recent creation of the Saudi Breast Cancer Trialists' Group, part of the Cancer Trialists' Group (CTG).

(v) Development of models and processes for the improvement of patient care and integration of innovative approaches in countries in transition, where the burden of cancer will double in the coming 20 years.

He is the author of more than 350 articles and abstracts as well as more than 1100 international presentations.



Dr. Ivo Olivotto, MD

Dr. Olivotto is Professor and Head of the Division of Radiation Oncology and Developmental Radiotherapeutics at the University of British Columbia and VP of Radiation Therapy and Functional Imaging for the BC Cancer Agency. His clinical practice and research career have focused on improving care and treatment for patients with breast cancer with a particular emphasis on outcomes evaluation, the impact of treatment guidelines and technical innovation. He founded the BC Cancer Agency's Breast Cancer Outcomes Unit and has had a leadership role provincially and nationally in clinical trials evaluating the role of radiation therapy in breast cancer. Since September 2013, Dr. Olivotto moved to University of Calgary as the Head of Radiation Oncology at the Tom Baker Cancer Center.



Dr. Joseph Pergolizzi, MD

Joseph V. Pergolizzi, Jr., MD, is an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland; former Adjunct Faculty member in the Department of Anesthesiology and Pain Medicine at Georgetown University School of Medicine in Washington, DC; and an Associate Professor in the Department of Pharmacology at Temple University School of Medicine in Philadelphia, PA; Dr. Pergolizzi is a steering committee member of the Food and Drug Administration's Safe Use Initiative and a consultant to the National Institute of Health.

Dr. Pergolizzi is the author of over 150 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise. He is an internationally recognized expert in clinical research, pain medicine, anesthesia, internal medicine, pharmacology, regulatory affairs and drug discovery. He has been awarded the American Medical Association Physician Recognition Award with Commendation and is a member of the Who's Who for International Executives. He has served as a member of advisory boards and medical/scientific societies, and has acted on a number of institutional committees including the Medical Errors Committee and Pharmacy and Therapeutics Committee. Dr. Pergolizzi is recognized by his peers as a scientific and medical expert who integrates new technologies into everyday clinical practice. He has been investigating the effectiveness, safety, and utility of various interventions for patients with acute and chronic disorders for several years.



Dr. Hope Rugo, MD

Dr. Rugo is Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, where she directs Breast Cancer and Clinical Trial Education. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care.

She is an investigator in, the national multicenter ISPY2 trial, and is the principal investigator of a number of clinical trials. She is 1 of 3 recipients of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, and serves on a number of steering committees for national and international trials. Dr. Rugo is a member of the ALLIANCE Breast Core Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network Guidelines Committee, and serves on several committees for the American Society of Clinical Oncology. She has published many peer-reviewed papers and has given presentations on a variety of breast cancer and supportive care-related topics.

With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her medical degree from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. In addition, she completed a 2-year postdoctoral fellowship in immunology at Stanford University. She received the Cancer Care Physician of the Year Award in 2010.



Dr. Barbara Smith, MD, PhD

Dr. Barbara Smith is the Director of the Breast Program at Massachusetts General Hospital. She is an Associate Professor of Surgery at Harvard Medical School and at the Massachusetts General Hospital.

Dr. Smith received her undergraduate training at MIT and an MD-PhD from Harvard Medical School.

Dr. Smith's research activities have focused on reducing the extent of surgery and radiation required to treat breast cancer, with particular attention to young and high risk women. She studies 3-dimensional breast microanatomy as it relates to breast surgery and pathologic analysis of specimens. She has developed improved techniques for nipple sparing mastectomy and reconstruction and leads one of the largest nipple sparing surgery programs in the United States.

She has been a Visiting Professor at Sun Yat-sen University in Guangzhou, China since 2006 and has been an Adjunct Professor of Breast Surgery at Hunan Provincial Tumor Hospital in Changsha, China since 2013. She lectures extensively at national and international breast cancer conferences.



Dr. Giuseppe Viale

Professor Viale is chairman of the Central Pathology Office and of the Biological Protocol Working Group of the International Breast Cancer Study Group and Lead Pathologist of the Breast International Group, Vice President for Europe of the Senologic International Society, and Member of the FFPE Working Group of the Breast International and NCI-sponsored breast cancer Cooperative Groups, of the Early Breast Cancer Trialists Collaborative Group Steering Committee, of the Pathology Sub-study Group of the Intergroup Exemestane Study, and Founding Member of the International Sentinel Node Society. He has been active in clinical and translational researches on breast carcinoma, with particular reference to the development of the axillary sentinel lymph node biopsy, to the identification of predictors of response to endocrine and cytotoxic therapies, to the clinical validation of gene expression signatures and to the biological and clinical effects of a deregulated Numb/Notch pathway. Professor Viale authored 276 articles in indexed international Journals and 36 chapters in books. Giuseppe Viale, MD, FRCPath Professor of Pathology and Chairman, University of Milan School of Medicine Director of the Department of Pathology and Laboratory Medicine, European Institute of Oncology in Milan.



Dr. Sandra Swain, M.D.

Sandra M. Swain, MD, FACP is the Medical Director of the Washington Cancer Institute, MedStar Washington Hospital Center, in Washington, DC. She is a Professor of Medicine at Georgetown University and Adjunct Professor of Medicine at F. Edward Hebert School of Medicine. She was previously the Deputy Branch Chief of the Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health and was a tenured Principal Investigator and Chief of the Breast Cancer Section and of the Cancer Therapeutics Branch. She obtained an undergraduate degree in Chemistry from the University of North Carolina in 1975, and a MD from the University of Florida in Gainesville in 1980. She completed her residency in internal medicine at Vanderbilt University in 1983 followed by a fellowship in Medical Oncology at the National Cancer Institute in 1986.

Dr. Swain's research interests include clinical trials and translational research in metastatic and inflammatory breast cancer, adjuvant therapy for breast cancer, cardiotoxicity, and health care disparities. Her research has been funded by the National Institutes of Health, Susan G. Komen Foundation, Breast Cancer Research Foundation, and the Avon Foundation. She has published over 230 articles and is recognized as a leading international figure in breast cancer. She received the Susan G. Komen for the Cure Community Global Award of Distinction in 2012. Dr. Swain was president of the American Society of Clinical Oncology (ASCO) in 2012-13, served as a member of the ASCO Board and is a member of the Conquer Cancer Foundation Board.